| [1] |
Li L，Ma BB.Colorectal cancer in Chinese patients：current and emerging treatment options[J].Onco Targets Ther，2014，7：1817-1828.
|
| [2] |
Van Cutsem E，Nordlinger B，Cervantes A，et al.Advanced colorectalcancer：ESMO Clinical Practice Guidelines for treatment[J].Ann Oncol，2010，21（Suppl 5）：93-97.
|
| [3] |
DeSantis CE，Lin CC，Mariotto AB，et al.Cancer treatment and survivorship statistics，2014[J].CA Cancer J Clin，2014，64（4）：252-271.
|
| [14] |
肖健，郑坚，黄艳，等.贝伐珠单抗联合同期放化疗新辅助治疗局部晚期直肠癌的病例系列研究[J].中华外科杂志，2014，52（11）：861-862.
|
| [4] |
Van Cutsem E，Köhne CH，Hitre E，et al.Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer[J].N Engl Med，2009，360（14）：1408-1417.
|
| [5] |
Duffaud F，Therasse P.New guidelines to evaluate the response to treatment in solid tumors[J].Bull Cancer，2000，87（12）：881-886.
|
| [6] |
Ayez N，Burger JW，Vander Pool AE，et al.Long-term results of the “liver first”approach in patients with locally advanced rectal cancer and synchronous liver metastases[J]. Dis Colon Rectum，2013，56（3）：281-287.
|
| [7] |
De Jong MC，Pulitano C，Ribero D，et al.Rates and patterns of recurrence following curative intent surgery for coloreetal liver metastasis：an international multi-institutional analysis of 1669 patients[J].Ann Surg，2009，250（3）：440-448.
|
| [8] |
Cetin B，Kaplan MA，Berk V，et al.Bevacizumab-containing chemotherapy is safe in patients with unresectable metastatic colorectal cancer and a synchronous asymptomatic primary tumor[J].Jpn J Clin Onclo，2013，43（1）：28-32.
|
| [9] |
Toumigand C，Andre T，Achille E，et al.FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer：a randomized GERCOR study[J].J Clin Oncol，2004，22（2）：229-237.
|
| [10] |
Koukourakis GV，Sotiropoulou-Lontou A.Targeted therapy with bevacizumab（Avastin）for metastatic coloractal cancer[J].Clin Transl Oncol，2011，13（10）：710-714.
|
| [11] |
Hurwitz H，Fehrenbachcr L，Novotny W，et al.Bevacizumab plus irinotecan，fluorouracil，and leucovorin for metastatic colorectal cancer[J]N Engl J Med，2004，350（23）：2335-2342.
|
| [12] |
Cartwright TH，Yim YM，Yu E，et al.Survival outcomes of bevaci-zumab beyond progression in metastatic colorectal cancer patients treated in US community oncology[J].Clin Colorectal Cancer，2012，11（4）：238-246.
|
| [13] |
Bendell JC，Bekaii-Saab TS，Cohn AL，et al.Treatment patterns and clinical outcomes in patients with metastatic colorectalcancerinitially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab：results from ARIES，a bevacizumab observational cohort study[J].Oncologist，2012，17（12）：1486-1495.
|
| [15] |
Van Cutsem E，Rivera F，Berry S，et al.Safety and efficacy of first-line bevacizumab with FOLFOX，XELOX，FOLFIRI and fuoropyrimidines in metastatic colorectal cancer：the BEAT study[J].Ann Oncol，2009，20（11）：1842-1847.
|
| [16] |
Hershman DL，Wright JD，Lim E，et al.Contraindicated use ofbevacizumab and toxicity in elderly patients with cancer[J]. J Clin Oncol，2013，31（28）：3592-3599.
|
